Octreotide use while Breastfeeding
Drugs containing Octreotide: Sandostatin, Sandostatin LAR Depot
Octreotide Levels and Effects while Breastfeeding
Summary of Use during Lactation
The excretion of octreotide into breastmilk has not been studied. However, because it is poorly absorbed orally and has been safely administered directly to infants by injection, it is unlikely to adversely affect the breastfed infant. One breastfed infant apparently experienced no adverse effects during maternal use of octreotide. Until more data are available, octreotide should be used in nursing mothers with careful infant monitoring, especially if the infant is under 2 months of age.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
One mother was treated for acromegaly during pregnancy and postpartum with octreotide (dose not stated). She breastfed (extent not stated) her infant for 4 months with no apparent problems noted in the infant.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
1. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777-81. PMID: 9284694
CAS Registry Number
- Antineoplastic Agents, Hormonal
- Gastrointestinal Agents
LactMed Record Number
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.